Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y385

UPID:
UB2J1_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme J1; Non-canonical ubiquitin-conjugating enzyme 1; Yeast ubiquitin-conjugating enzyme UBC6 homolog E

ALTERNATIVE UPACC:
Q9Y385; A8K3F9; Q53F25; Q5W0N4; Q9BZ32; Q9NQL3; Q9NY66; Q9P011; Q9P0S0; Q9UF10

BACKGROUND:
The Ubiquitin-conjugating enzyme E2 J1, known for its roles in the ERAD pathway, MAPKAPK2-dependent TNF-alpha synthesis, and perinuclear positioning of the endosomal system, is a key player in cellular stress response and viral infection defense. It functions by attaching ubiquitin to proteins, a process crucial for protein degradation and signal transduction pathways. Its interaction with RNF26 and effect on SQSTM1 ubiquitination highlight its importance in cellular organization and immune response.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin-conjugating enzyme E2 J1 offers a promising avenue for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.